BEAM: חובות מצטברים של החברה beamtx.com

By leveraging established DNA material logistics through its laboratory network, Beam Therapeutics Inc. (BEAM) maintains high profitability. The GURU.Markets platform transmits debt dynamics, where 0.23 reflects the latest metric value. Quotes depend on BEAM-101 trials and lipid nanoparticles, while the environmental profile is limited by strict bio-waste control at research centers.

This indicator aggregates all short-term and long-term liabilities, allowing the investor to assess the total debt load and the risk of insolvency. The dynamics of the leverage ratio reflect the balance between securing external financing and its repayment, which is critically important for Beam Therapeutics Inc. (BEAM), as negative operating cash flow during the development stage necessitates rigorous control over the liability structure.